Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00418-025-02410-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Correction: Angiopoietins: multifaceted mediators in the pathogenesis of joint-related disorders.
Histochem Cell Biol
September 2025
Stomatology Hospital, School of Stomatology, Zhejiang Provincial Clinical Research Center for Oral Diseases, Key Laboratory of Oral Biomedical Research of Zhejiang Province, Cancer Center of Zhejiang University, Engineering Research Center of Oral Biomaterials and Devices of Zhejiang Province, Zheji
Proteomic Biomarkers Are Linked to QTc Interval in Patients With Chronic Heart Failure.
Proteomics Clin Appl
September 2025
Department of Cardiology, Thorax Center, Cardiovascular Institute, Erasmus MC, Rotterdam, the Netherlands.
Objective: This study investigates the link between circulating proteins and rate-corrected QT (QTc) interval in patients with heart failure with reduced ejection fraction (HFrEF) and their association with cardiovascular outcomes.
Methods And Results: We analyzed 197 HFrEF patients from the prospective Serial Biomarker Measurements and New Echocardiographic Techniques in Chronic Heart Failure Patients Result in Tailored Prediction of Prognosis (Bio-SHiFT) study, all in sinus rhythm at baseline. Baseline QTc intervals were calculated and corrected for broad QRS complexes (>120 ms) using Bogossian's formula.
Real-World Clinical Experience With Monthly Faricimab for Treatment-Naïve Diabetic Macular Edema: A Case Series From an Indian Tertiary Care Center.
Cureus
July 2025
Department of Retina, Sarojini Devi Eye Hospital, Hyderabad, IND.
This case series explores the efficacy and safety of a monthly loading dose regimen of intravitreal faricimab in treatment-naïve patients with diabetic macular edema (DME) in an Indian clinical setting. In this retrospective analysis, five adult patients with treatment-naïve DME received faricimab (four intravitreal injections of 6 mg) on Day 0, Day 30, Day 60, and Day 90. Their best-corrected visual acuity (BCVA) and central macular thickness (CMT) were evaluated throughout the study.
View Article and Find Full Text PDFSwitching to faricimab alleviates persistent subretinal fluid and pigment epithelial detachment in neovascular age-related macular degeneration.
Jpn J Ophthalmol
August 2025
Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan.
Purpose: To evaluate structural outcomes, including subretinal fluid (SRF) and fibrovascular pigment epithelial detachment (fvPED) volume changes, after switching from aflibercept 2 mg to faricimab in Japanese patients with neovascular age-related macular degeneration (nAMD).
Study Design: Retrospective, observational study.
Methods: Patients with nAMD who were switched from aflibercept 2 mg to faricimab were enrolled.
IMPACT OF FARICIMAB VERSUS AFLIBERCEPT ON EPIRETINAL MEMBRANE FORMATION OVER 2 YEARS IN PATIENTS WITH DIABETIC MACULAR EDEMA IN THE PHASE 3 YOSEMITE AND RHINE TRIALS.
Retina
July 2025
Genentech, Inc., South San Francisco, California.
Purpose: To assess the effects of faricimab versus aflibercept on epiretinal membrane (ERM) formation in eyes with diabetic macular edema (DME).
Methods: Post hoc analysis of phase 3 YOSEMITE/RHINE trial data in eyes with DME receiving faricimab Q8W, faricimab treat-and-extend (T&E; up to Q16W depending on central subfield thickness [CST] and best-corrected visual acuity [BCVA]), or aflibercept Q8W for 100 weeks.
Results: ERMs developed in 3.